Contract analysis

I. EXECUTIVE SUMMARY The purpose of this memorandum is to provide a preliminary quantification of the damages available to Meridian Consumer Brands LLC ("Meridian" or "MCB") in its anticipated federal action against Apex Naturals Inc. ("Apex") arising from Apex's false and misleading comparative advertising campaign marketed under the name "The PuraClear Truth," which was launched nationally on June 2, 2025. This ass

1. Compensatory Damages in the Form of Lost Profits. Meridian's DermaTrūe acne-treatment product line experienced a significant revenue decline in the third quarter of 2025, temporally correlated with and causally attributable to the false campaign. The lost gross profits for Q3 2025 are estimated at $4.625 million, yielding an annualized lost-profit estimate of approximately $18.5 million if the campaign continues u

2. Disgorgement of Apex's Incremental Profits. Apex's PuraClear product line experienced above-trend revenue growth during the same period, generating an estimated $19.8 million in incremental revenue attributable to the false campaign. At Apex's estimated gross margin of 56.5%, the disgorgeable incremental profits total approximately $11.2 million.

3. Enhanced (Treble) Damages Under the Lanham Act. If the Court finds that Apex acted willfully — and the fabricated clinical study citation and Apex's post-NAD defiance provide strong evidence of willfulness — the Lanham Act authorizes treble damages up to $55.5 million (i.e., $18.5 million × 3). In addition to the foregoing, Meridian faces an imminent and independently quantifiable harm: Kingsley Drug Stores LLC, o

II. BACKGROUND AND FACTUAL PREDICATE A. The Parties Meridian Consumer Brands LLC. Meridian is a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001. Meridian develops, markets, and distributes premium skincare and personal-care products through a diversified portfolio of brands sold in mass-market retail, specialty retail, and direct-to

III. COMPENSATORY DAMAGES — LOST PROFITS ANALYSIS A. Legal Framework The Lanham Act provides the primary statutory basis for Meridian's compensatory damages claim. Under Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), a plaintiff who prevails on a claim of false advertising under Section 43(a) of the Act, 15 U.S.C. § 1125(a), is entitled to recover "any damages sustained by the plaintiff" as a result of the def

IV. DISGORGEMENT OF DEFENDANT'S PROFITS A. Legal Framework In addition to compensatory damages in the form of the plaintiff's lost profits, Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), authorizes recovery of "defendant's profits" as a separate measure of relief. The availability of disgorgement serves both a compensatory function — ensuring that the plaintiff is made whole for injuries that may be difficult

V. ENHANCED (TREBLE) DAMAGES UNDER THE LANHAM ACT A. Legal Framework

Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), grants the court discretion to "enter judgment, according to the circumstances of the case, for any sum above the amount found as actual damages, not exceeding three times such amount." This enhancement provision permits the court to treble the plaintiff's actual damages award in cases where the defendant's conduct is found to be willful or where the case is deeme

VI. ADDITIONAL DAMAGES — KINGSLEY DRUG STORES SHELF-SPACE REDUCTION A. Factual Basis On August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), one of Meridian's largest and most strategically important retail partners, notified Meridian's sales team that it was reducing the DermaTrūe product line's shelf space allocation by 30%, effective October 1, 2025. Kingsley is a major national retail chain operating over 2,400

VII. SUMMARY OF PRELIMINARY DAMAGES ESTIMATES A. Tabular Summary The following table summarizes the preliminary damages estimates across all categories analyzed in this memorandum: B. Range of Total Recovery Based on the foregoing analysis, the range of potential total recovery is as follows: Conservative (lost profits only, no enhancement): Approximately $18.5–$21.1 million per year of continuing harm, representing

VIII. DATA GAPS AND DISCOVERY PRIORITIES The damages estimates set forth in this memorandum are based on the best available data as of the date of this memorandum. However, as noted throughout, several critical data points are estimated or unavailable and will require targeted discovery to validate and refine. This section identifies the key data gaps and outlines the corresponding discovery priorities. A. Informatio

1. PuraClear Sales Data. Actual unit and revenue data for all PuraClear products for the period from Q1 2024 through Q3 2025, broken down by SKU, distribution channel (e.g., retail, e-commerce, direct-to-consumer), and geographic market. This data is essential to validate the preliminary estimate of $19.8 million in incremental PuraClear revenue and to refine the disgorgement calculation in Dr. Choe's formal model.

2. Cost of Goods Sold and Margin Data. Actual cost of goods sold and gross margin figures for PuraClear products, including raw material costs, manufacturing costs, packaging costs, and direct labor allocations. This data is needed to replace the estimated 56.5% gross margin with verified figures and to provide Apex the opportunity to meet its burden of proving deductible costs under the Lanham Act's burden-shifting

3. Campaign Spend Documentation. Detailed invoices, media-buy records, and insertion orders from Brightline Creative Partners LLC (Owen Prescott, Chief Creative Officer), Apex's advertising agency of record, to verify the estimated $23.0 million total campaign spend and to analyze the deductibility vel non of those expenditures. We will also seek Apex's internal budget documents and approval records for the "Project

4. Clinical Study Underlying the Superiority Claim. All protocols, raw data, subject-consent forms, statistical analyses, draft and final reports, and internal and external communications relating to the 22-person pilot study and the purported "Guerrero et al., 2024, Independent Dermatological Review" publication. This material is critical to establishing the fabrication of the clinical citation and to supporting the

5. Internal Communications. Emails, text messages, instant messages (including Meridian Solutions, Teams, or other internal messaging platforms), memoranda, meeting notes, and other documents among Marcus Devlin (CEO), Rachel Emory (CMO), Dr. Simon Guerrero (VP, Product Development), Tanya Fischetti (General Counsel), and any other Apex personnel involved in the conception, development, approval, or continuation of t

6. Retailer Sales Data. Apex's sales data through Kingsley Drug Stores LLC and comparable major retail channels, to assess whether PuraClear gained corresponding shelf space or sales volume as DermaTrūe lost shelf space and sales. This data will support the causation and tortious interference theories and will help Dr. Choe model the overlap between the lost-profits and disgorgement calculations. B. Information Neede

1. Kingsley Drug Stores LLC. We will serve third-party subpoenas on Kingsley seeking documentation of the shelf-space decision, including internal analyses of DermaTrūe sales performance, category management reports, and any communications between Kingsley and Apex (or Apex's representatives) regarding PuraClear product placement, promotional support, or shelf-space allocation. This documentation will be critical to

2. Additional Retailer Data. We will also seek sales-through and market-share data from other major retail and e-commerce channels through which both DermaTrūe and PuraClear are sold. This data will corroborate the causal link between the campaign and DermaTrūe's overall revenue decline and will help establish that the impact was not limited to a single retail channel but was felt across Meridian's entire distributio

1. Dr. Raymond Choe, Marlowe Asset Management Economic Consulting LLC ($925/hr). Dr. Choe will prepare the formal damages report, including: (a) a rigorous lost-profits model incorporating but-for revenue analysis, margin verification, and incremental-cost assessment; (b) a disgorgement analysis based on Apex's actual financial data (once obtained in discovery); (c) an overlap assessment to determine the extent to wh

2. Dr. Eleanor Fisk, Fisk Analytics Group LLC ($850/hr). Dr. Fisk has already conducted the post-campaign consumer perception survey referenced throughout this memorandum. She may be called upon to conduct supplemental survey work if needed to establish additional consumer-confusion and materiality metrics for purposes of the damages causation analysis. In particular, if Apex challenges the causal link between the ca

3. Dr. Miriam Salazar, Graystone University Medical Center ($750/hr). Dr. Salazar, a board-certified dermatologist and clinical researcher, will provide a scientific rebuttal of the clinical superiority claim. Her testimony will address the methodological deficiencies of the 22-person pilot study (lack of blinding, absence of a control group, inadequate sample size), the non-existence of the cited "Guerrero et al., 2

IX. PRELIMINARY INJUNCTION DAMAGES CONSIDERATIONS The damages analysis set forth in this memorandum serves an important dual purpose: in addition to quantifying the potential monetary recovery, the analysis supports the showing of irreparable harm that is essential to Meridian's forthcoming motion for a preliminary injunction, which we intend to file on September 26, 2025. For purposes of the preliminary injunction s